Skip to content
Longterm Wiki

Charak Foundation — Ramatroban Clinical Trial

$1M
Funder
Recipient
Charak Foundation
Program
Date
Mar 2022
Data source
Source
Notes

[Human Health and Wellbeing] Open Philanthropy recommended a grant of $1,015,686.03 to the Charak Foundation to fund the initial stages of a clinical trial of ramatroban for the suppression of life-threatening symptoms of COVID-19 infections. Ramatroban is a pill approved for sale and use against allergic rhinitis in Japan, and has been used for over twenty years without incident. The trial will involve the recruitment of people who have been admitted to hospitals with COVID-19. The treatment cohort will be followed for 4-6 months to assess outcomes that include mortality, hypoxemia, length of hospital stay, cytopenia, pulmonary fibrosis, and symptoms related to “long COVID.” This falls within our focus area of scientific research, and specifically within our interest in advancing human health and wellbeing. The grant amount was updated in May 2025.

Other Grants by Coefficient Giving

2625
Showing 10 of 2625 grants
Charak Foundation — Ramatroban Clinical Trial | Coefficient Giving | Grants | Longterm Wiki